Byron J Hoogwerf Selected Research

basal insulin peglispro

1/2018	Cytokeratin-18 and enhanced liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins.
11/2017	Effects of hepato-preferential basal insulin peglispro on nuclear magnetic resonance biomarkers lipoprotein insulin resistance index and GlycA in patients with diabetes.
1/2017	The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes.
5/2016	Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Byron J Hoogwerf Research Topics

Disease

30	Type 2 Diabetes Mellitus (MODY) 01/2023 - 11/2003
10	Body Weight (Weight, Body) 09/2012 - 04/2007
9	Hypoglycemia (Reactive Hypoglycemia) 05/2021 - 04/2007
7	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 02/2021 - 06/2003
6	Diabetes Mellitus 01/2023 - 03/2004
6	Cardiovascular Diseases (Cardiovascular Disease) 08/2016 - 11/2003
5	Myocardial Infarction 01/2018 - 03/2010
5	Insulin Resistance 11/2017 - 12/2002
4	Nausea 01/2013 - 04/2007
4	Hypertension (High Blood Pressure) 08/2011 - 06/2008
4	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2010 - 12/2002
4	Heart Failure 06/2008 - 03/2003
3	Non-alcoholic Fatty Liver Disease 01/2018 - 01/2017
3	Stroke (Strokes) 01/2018 - 03/2011
3	Vomiting 01/2013 - 04/2007
3	Weight Loss (Weight Reduction) 07/2012 - 01/2008
3	Coronary Disease (Coronary Heart Disease) 08/2011 - 03/2002
3	Weight Gain 01/2011 - 04/2003
3	Proteinuria 04/2004 - 03/2003
2	Myocardial Ischemia (Ischemic Heart Diseases) 01/2018 - 01/2011
2	Hyperglycemia 10/2014 - 03/2011
2	Dyslipidemias (Dyslipidemia) 08/2011 - 03/2004
2	Atherosclerosis 08/2004 - 02/2003
2	Renal Insufficiency (Renal Failure) 04/2004 - 11/2003
1	Cognitive Dysfunction 01/2020
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2018
1	Unstable Angina 01/2018
1	Inflammation (Inflammations) 11/2017
1	Hepatocellular Carcinoma (Hepatoma) 01/2017
1	Fibrosis (Cirrhosis) 01/2017
1	Kidney Diseases (Kidney Disease) 08/2013
1	Hypothyroidism 08/2011
1	Acute Coronary Syndrome 03/2011
1	Constipation 01/2011
1	Diarrhea 01/2011
1	Headache (Headaches) 01/2011
1	Obesity 01/2011
1	Ischemic Stroke 01/2011
1	Hyperlipidemias (Hyperlipidemia) 01/2011
1	Hypotension (Low Blood Pressure) 09/2010
1	Cough 01/2010
1	Angioedema 01/2010
1	Peripheral Arterial Disease 01/2010
1	Diabetes Complications 06/2008

Drug/Important Bio-Agent (IBA)

17	Glucose (Dextrose)FDA LinkGeneric 05/2021 - 03/2006
17	Insulin (Novolin)FDA Link 05/2021 - 04/2003
12	Exenatide (Byetta)FDA Link 08/2013 - 05/2006
5	Insulin Glargine (Lantus)FDA Link 01/2018 - 01/2011
5	Blood Glucose (Blood Sugar)IBA 07/2010 - 03/2002
4	basal insulin peglisproIBA 01/2018 - 05/2016
4	Biomarkers (Surrogate Marker)IBA 11/2017 - 01/2008
4	LipidsIBA 01/2017 - 06/2008
4	Triglycerides (Triacylglycerol)IBA 01/2017 - 04/2004
4	Hemoglobins (Hemoglobin)IBA 09/2012 - 06/2003
4	2,4-thiazolidinedione (thiazolidinedione)IBA 03/2012 - 12/2002
4	HDL CholesterolIBA 09/2010 - 04/2004
4	CholesterolIBA 06/2008 - 12/2002
4	CreatinineIBA 04/2004 - 03/2003
3	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 02/2021 - 06/2008
3	InsulinsIBA 01/2018 - 05/2016
3	Glucagon-Like Peptide-1 ReceptorIBA 10/2014 - 01/2010
3	Metformin (Glucophage)FDA LinkGeneric 03/2012 - 04/2007
3	Ramipril (Altace)FDA LinkGeneric 01/2010 - 03/2003
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2023 - 03/2004
2	oxidized low density lipoproteinIBA 01/2017 - 09/2010
2	Rosiglitazone (Avandia)FDA Link 08/2016 - 06/2008
2	omega-Chloroacetophenone (Mace)IBA 05/2016 - 03/2011
2	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2013 - 06/2012
2	IncretinsIBA 06/2012 - 06/2008
2	Hemoglobin AIBA 03/2012 - 04/2007
2	HomocysteineIBA 08/2011 - 06/2008
2	Pioglitazone (Actos)FDA Link 01/2011 - 06/2008
2	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2011 - 06/2008
2	HDL LipoproteinsIBA 03/2010 - 01/2005
2	Fibrinogen (Factor I)FDA Link 06/2008 - 02/2008
2	C-Reactive ProteinIBA 06/2008 - 09/2003
2	LDL CholesterolIBA 06/2008 - 08/2004
2	pramlintide (Symlin)FDA Link 01/2008 - 05/2006
1	Insulin Lispro (Humalog)FDA Link 02/2021
1	Insulin Aspart (NovoLog)FDA Link 01/2021
1	LinagliptinIBA 07/2020
1	Keratin-18 (Keratin 18)IBA 01/2018
1	Lipoproteins (Lipoprotein)IBA 11/2017
1	AdiponectinIBA 01/2017
1	Liraglutide FDA Link 01/2013
1	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 06/2012
1	Dipeptidyl-Peptidase IV InhibitorsIBA 06/2012
1	Hypoglycemic Agents (Hypoglycemics)IBA 03/2012
1	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 08/2011
1	Long-Acting Insulin (Insulin, Long Acting)FDA Link 01/2011
1	lipoprotein cholesterolIBA 09/2010
1	Telmisartan (Micardis)FDA Link 01/2010
1	Apolipoproteins AIBA 06/2008
1	Lipoprotein(a)IBA 06/2008

Therapy/Procedure

16	Therapeutics 11/2017 - 04/2003
10	Glycemic Control 01/2023 - 04/2007
2	Injections 01/2013 - 01/2011
2	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 08/2004 - 02/2003
1	Liver Transplantation 01/2017
1	Ambulatory Care (Outpatient Care) 09/2012